Consuelo Vicente
Research Subjects
Research Interests
Consuelo Vicente has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- José Ruiz
Departamento de Química Inorgánica, Universidad de Murcia, and Murcia BioHealth Research Institute (IMIB-Arrixaca), E-30100 Murcia, Spain
29 shared publications Gregorio López
15 shared publications- Venancio Rodríguez
Departamento de Química Inorgánica
11 shared publications - Natalia Cutillas
Departamento de Química Inorgánica, Universidad de Murcia and Institute for Bio-Health Research of Murcia (IMIB-Arrixaca), E-30071 Murcia, Spain
8 shared publications Delia Bautista
7 shared publications- Concepción de Haro
Departamento de Química Inorgánica, Facultad de Química, Universidad de Murcia, Murcia, Spain
6 shared publications
Latest Publications
- 6 July 2017
- Published by American Chemical Society (ACS) in Journal of Chemical Theory and Computation
- Vol. 13 (8) , 3898-3910
DFT Simulation of Structural and Optical Properties of 9-Aminoacridine Half-Sandwich Ru(II), Rh(III), and Ir(III) Antitumoral Complexes and Their Interaction with DNA
In this work, we use DFT-based methods to simulate the chemical structures, optical properties, and interaction with DNA of a recently synthesized chelated C^N 9-aminoacridine arene Ru(II) anticancer agent and two new closely related Rh(III) and Ir(III) complexes using DFT-based methods. Four chemical models and a number of theoretical approaches, which representatively include the PBE0, B97D, ωB97X, ωB97X-D, M06, and M06-L density functionals and the LANL2DZ, def2-SVP, and def2-TZVP basis sets, are tested. The best overall accuracy/cost performance for the optimization process is reached at the ωB97X-D/def2-SVP and M06/def2-SVP levels of theory. Inclusion of explicit solvent molecules (CHCl3) further refines the geometry, while taking into account the crystal network gives no significant improvements of the computed bond distances and angles. The analysis of the excited states reveals that the M06 level matches better the experimental absorption spectra, compared to ωB97X-D. The use of the M06/def2-SVP approach is therefore a well-balanced method to study theoretically the bioactivity of this type of antitumoral complexes, so we couple this TD-DFT approach to molecular dynamics simulations in order to assess their reactivity with DNA. The reported results demonstrate that these drugs could be used to inject electrons into DNA, which might broaden their applications in photoactivated chemotherapy and as new materials for DNA-based electrochemical nanodevices.
- 6 July 2017
- Published by American Chemical Society (ACS) in Journal of Chemical Theory and Computation
- Vol. 13 (8) , 3898-3910
DFT Simulation of Structural and Optical Properties of 9-Aminoacridine Half-Sandwich Ru(II), Rh(III), and Ir(III) Antitumoral Complexes and Their Interaction with DNA
In this work, we use DFT-based methods to simulate the chemical structures, optical properties, and interaction with DNA of a recently synthesized chelated C^N 9-aminoacridine arene Ru(II) anticancer agent and two new closely related Rh(III) and Ir(III) complexes using DFT-based methods. Four chemical models and a number of theoretical approaches, which representatively include the PBE0, B97D, ωB97X, ωB97X-D, M06, and M06-L density functionals and the LANL2DZ, def2-SVP, and def2-TZVP basis sets, are tested. The best overall accuracy/cost performance for the optimization process is reached at the ωB97X-D/def2-SVP and M06/def2-SVP levels of theory. Inclusion of explicit solvent molecules (CHCl3) further refines the geometry, while taking into account the crystal network gives no significant improvements of the computed bond distances and angles. The analysis of the excited states reveals that the M06 level matches better the experimental absorption spectra, compared to ωB97X-D. The use of the M06/def2-SVP approach is therefore a well-balanced method to study theoretically the bioactivity of this type of antitumoral complexes, so we couple this TD-DFT approach to molecular dynamics simulations in order to assess their reactivity with DNA. The reported results demonstrate that these drugs could be used to inject electrons into DNA, which might broaden their applications in photoactivated chemotherapy and as new materials for DNA-based electrochemical nanodevices.
- 19 April 2017
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 12 (6) , 1524-1537
New Acridine Thiourea Gold(I) Anticancer Agents: Targeting the Nucleus and Inhibiting Vasculogenic Mimicry
Two new 1-acridin-9-yl-3-methylthiourea Au(I) DNA intercalators [Au(ACRTU)2]Cl (2) and [Au(ACRTU) (PPh3)]PF6 (3) have been prepared. Both complexes were highly active in the human ovarian carcinoma cisplatin-sensitive A2780 cell line, exhibiting IC50 values in the submicromolar range. Compounds 2 and 3 are also cytotoxic toward different phenotypes of breast cancer cell lines MDA-MB-231 (triple negative), SK-BR-3 (HER2+, ERα–, and ERβ−), and MCF-7 (ER+). Both complexes induce apoptosis through activation of caspase-3 in vitro. While inhibition of some proteins (thiol-containing enzymes) seems to be the main mechanism of action for cytotoxic gold complexes, 2 and 3 present a DNA-dependent mechanism of action. They locate in the cell nucleus according to confocal microscopy and transmission electronic microscopy. The binding to DNA resulted to be via intercalation as shown by spectroscopic methods and viscometry, exhibiting a dose-dependent response on topoisomerase I mediated DNA unwinding. In addition, 2 and 3 exhibit potent antiangiogenic effects and are also able to inhibit vasculogenic mimicry of highly invasive MDA-MB-231 cells.
- 19 April 2017
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 12 (6) , 1524-1537
New Acridine Thiourea Gold(I) Anticancer Agents: Targeting the Nucleus and Inhibiting Vasculogenic Mimicry
Two new 1-acridin-9-yl-3-methylthiourea Au(I) DNA intercalators [Au(ACRTU)2]Cl (2) and [Au(ACRTU) (PPh3)]PF6 (3) have been prepared. Both complexes were highly active in the human ovarian carcinoma cisplatin-sensitive A2780 cell line, exhibiting IC50 values in the submicromolar range. Compounds 2 and 3 are also cytotoxic toward different phenotypes of breast cancer cell lines MDA-MB-231 (triple negative), SK-BR-3 (HER2+, ERα–, and ERβ−), and MCF-7 (ER+). Both complexes induce apoptosis through activation of caspase-3 in vitro. While inhibition of some proteins (thiol-containing enzymes) seems to be the main mechanism of action for cytotoxic gold complexes, 2 and 3 present a DNA-dependent mechanism of action. They locate in the cell nucleus according to confocal microscopy and transmission electronic microscopy. The binding to DNA resulted to be via intercalation as shown by spectroscopic methods and viscometry, exhibiting a dose-dependent response on topoisomerase I mediated DNA unwinding. In addition, 2 and 3 exhibit potent antiangiogenic effects and are also able to inhibit vasculogenic mimicry of highly invasive MDA-MB-231 cells.
- Top Cited Papers
- 1 October 2013
- Published by Elsevier in Coordination Chemistry Reviews
- Vol. 257 (19-20) , 2784-2797
Anticancer cyclometalated complexes of platinum group metals and gold
- 1 October 2013
- Published by Elsevier in Coordination Chemistry Reviews
- Vol. 257 (19-20) , 2784-2797
Top Cited PapersAnticancer cyclometalated complexes of platinum group metals and gold
- 9 January 2013
- Published by American Chemical Society (ACS) in Inorganic Chemistry
- Vol. 52 (2) , 974-982
Novel Bis-C,N-Cyclometalated Iridium(III) Thiosemicarbazide Antitumor Complexes: Interactions with Human Serum Albumin and DNA, and Inhibition of Cathepsin B
A series of new organoiridium(III) complexes [Ir(N–C)2(N–S)]Cl (HN–C = 2-phenylpyridine (Hppy), N–S = methyl thiosemicarbazide (1), phenyl thiosemicarbazide (2) and naphtyl thiosemicarbazide (3)) have been synthesized and characterized. The crystal structure of (1) has been established by X-ray diffraction, showing the thiosemicarbazide ligand bound to the iridium atom as N,S-chelate. The cytotoxicity studies show that they are more active than cisplatin (about 5-fold) in T47D (breast cancer) at 48 h incubation time. On the other hand, very low resistance factors (RF) of 1–3 in A2780cisR (cisplatin-resistant ovarian carcinoma) at 48 h were observed (RF ≈ 1). Ir accumulation in T47D cell line after 48 h continuous exposure for complexes 1–3 are higher than that corresponding to cisplatin (about 10 times). The complexes 1–3 bind strongly to HSA with binding constants of about 104 M–1 at 296 K, binding occurring at the warfarin site I for 2. Complexes 2 and 3 are also capable of binding in the minor groove of DNA as shown by Hoechst 33258 displacement experiments. Furthermore, complex 2 is also a good cathepsin B inhibitor (an enzyme implicated in a number of cancer related events), being the enzyme reactivated by cysteine.
- 9 January 2013
- Published by American Chemical Society (ACS) in Inorganic Chemistry
- Vol. 52 (2) , 974-982
Novel Bis-C,N-Cyclometalated Iridium(III) Thiosemicarbazide Antitumor Complexes: Interactions with Human Serum Albumin and DNA, and Inhibition of Cathepsin B
A series of new organoiridium(III) complexes [Ir(N–C)2(N–S)]Cl (HN–C = 2-phenylpyridine (Hppy), N–S = methyl thiosemicarbazide (1), phenyl thiosemicarbazide (2) and naphtyl thiosemicarbazide (3)) have been synthesized and characterized. The crystal structure of (1) has been established by X-ray diffraction, showing the thiosemicarbazide ligand bound to the iridium atom as N,S-chelate. The cytotoxicity studies show that they are more active than cisplatin (about 5-fold) in T47D (breast cancer) at 48 h incubation time. On the other hand, very low resistance factors (RF) of 1–3 in A2780cisR (cisplatin-resistant ovarian carcinoma) at 48 h were observed (RF ≈ 1). Ir accumulation in T47D cell line after 48 h continuous exposure for complexes 1–3 are higher than that corresponding to cisplatin (about 10 times). The complexes 1–3 bind strongly to HSA with binding constants of about 104 M–1 at 296 K, binding occurring at the warfarin site I for 2. Complexes 2 and 3 are also capable of binding in the minor groove of DNA as shown by Hoechst 33258 displacement experiments. Furthermore, complex 2 is also a good cathepsin B inhibitor (an enzyme implicated in a number of cancer related events), being the enzyme reactivated by cysteine.
- 1 January 2012
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 41 (1) , 300-306
Studying the interactions of a platinum(ii) 9-aminoacridine complex with proteins and oligonucleotides by ESI-TOF MS
The interaction of a novel Pt complex, [Pt(dmba)(N9-9AA)(PPh3)]+1 (dmba = N,N-dimethylbenzylamine-κN,κC; 9AA = 9-aminoacridine), which exhibits anti-tumor activity, with certain key proteins has been monitored by ESI-MS. Also, the interaction of 1 with a designed double-stranded oligonucleotide containing the GG motif has been followed by mass spectrometry as well as by fluorimetry. The results obtained show the low interaction of 1 with the considered proteins and the absence of covalent interaction with the oligonucleotides, but the fluorimetric data confirm the π–π interaction of 1 with the double-stranded DNA, which is probably the reason of the previously reported activity of 1 in several tumor cell lines.
- 1 January 2012
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 41 (1) , 300-306
Studying the interactions of a platinum(ii) 9-aminoacridine complex with proteins and oligonucleotides by ESI-TOF MS
The interaction of a novel Pt complex, [Pt(dmba)(N9-9AA)(PPh3)]+1 (dmba = N,N-dimethylbenzylamine-κN,κC; 9AA = 9-aminoacridine), which exhibits anti-tumor activity, with certain key proteins has been monitored by ESI-MS. Also, the interaction of 1 with a designed double-stranded oligonucleotide containing the GG motif has been followed by mass spectrometry as well as by fluorimetry. The results obtained show the low interaction of 1 with the considered proteins and the absence of covalent interaction with the oligonucleotides, but the fluorimetric data confirm the π–π interaction of 1 with the double-stranded DNA, which is probably the reason of the previously reported activity of 1 in several tumor cell lines.
- 11 February 2011
- Published by American Chemical Society (ACS) in Inorganic Chemistry
- Vol. 50 (6) , 2151-2158
Synthesis and Antiproliferative Activity of a C,N-Cycloplatinated(II) Complex with a Potentially Intercalative Anthraquinone Pendant
The synthesis of the novel anthraquinone platinum derivate [Pt(ppy)Cl(1C3)] (2) [Hppy = N,C-chelating 2-phenylpyridine; 1C3 = 1-[(3-aminopropyl)amino]-anthracene-9,10-dione] and its values of IC50 against a panel of human tumor cell lines representative of ovarian (A2780 and A2780cisR) and breast cancers (T47D) are reported. At 24 h incubation time, complex 2 was more active than cisplatin (about 9-fold) and the free ligand 1C3 (about 2-fold) in T47-D. The observation that the cisplatin IC50 falls by about 10-fold from 24 to 72 h, whereas that for 2 changes little, suggests substantial differences in the mode of action. Complex 2 also showed high cytotoxicity against A2780 (about 3-fold greater than cisplatin at 24 h). On the other hand, very low resistance factors (RF) of 2 in A2780cisR at 24−72 h (RF = 1.3) were observed. The interaction of 2 with DNA was followed by electrophoretic mobility and UV−visible spectroscopy, and its reaction with the model nucleobase 9-EtG was studied by 1H NMR and ESI-MS. Theoretical calculations at the B3LYP/def2-TZVPP//BP86/def2-TZVP level of theory on complex 2 show a labile Pt−Cl bond that allows easy replacement of Cl by N-nucleophiles such as 9-EtG, which forms a stronger Pt−N bond.
- 11 February 2011
- Published by American Chemical Society (ACS) in Inorganic Chemistry
- Vol. 50 (6) , 2151-2158
Synthesis and Antiproliferative Activity of a C,N-Cycloplatinated(II) Complex with a Potentially Intercalative Anthraquinone Pendant
The synthesis of the novel anthraquinone platinum derivate [Pt(ppy)Cl(1C3)] (2) [Hppy = N,C-chelating 2-phenylpyridine; 1C3 = 1-[(3-aminopropyl)amino]-anthracene-9,10-dione] and its values of IC50 against a panel of human tumor cell lines representative of ovarian (A2780 and A2780cisR) and breast cancers (T47D) are reported. At 24 h incubation time, complex 2 was more active than cisplatin (about 9-fold) and the free ligand 1C3 (about 2-fold) in T47-D. The observation that the cisplatin IC50 falls by about 10-fold from 24 to 72 h, whereas that for 2 changes little, suggests substantial differences in the mode of action. Complex 2 also showed high cytotoxicity against A2780 (about 3-fold greater than cisplatin at 24 h). On the other hand, very low resistance factors (RF) of 2 in A2780cisR at 24−72 h (RF = 1.3) were observed. The interaction of 2 with DNA was followed by electrophoretic mobility and UV−visible spectroscopy, and its reaction with the model nucleobase 9-EtG was studied by 1H NMR and ESI-MS. Theoretical calculations at the B3LYP/def2-TZVPP//BP86/def2-TZVP level of theory on complex 2 show a labile Pt−Cl bond that allows easy replacement of Cl by N-nucleophiles such as 9-EtG, which forms a stronger Pt−N bond.
- 12 May 2009
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- No. 26,p. 5071-5073
A novel ruthenium(ii) arene based intercalator with potent anticancer activity
The new ruthenium(II) compound [(η6-p-cymene)Ru(N⁁C)Cl] (HN⁁C = 9-aminoacridine (9-HAA)) shows a potent in vitro anticancer activity.
- 12 May 2009
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- No. 26,p. 5071-5073
A novel ruthenium(ii) arene based intercalator with potent anticancer activity
The new ruthenium(II) compound [(η6-p-cymene)Ru(N⁁C)Cl] (HN⁁C = 9-aminoacridine (9-HAA)) shows a potent in vitro anticancer activity.
- 1 July 2008
- Published by American Chemical Society (ACS) in Inorganic Chemistry
- Vol. 47 (15) , 6990-7001
New Palladium(II) and Platinum(II) Complexes with 9-Aminoacridine: Structures, Luminiscence, Theoretical Calculations, and Antitumor Activity
The new complexes [Pd(dmba)(N10-9AA)(PPh3)]ClO4 (1), [Pt(dmba)(N9-9AA)(PPh3)]ClO4 (2), [Pd(dmba)(N10-9AA)Cl] (3), and [Pd(C6F5)(N10-9AA)(PPh3)Cl] (4) (9-AA = 9-aminoacridine; dmba = N,C-chelating 2-(dimethylaminomethyl)phenyl) have been prepared. The crystal structures have been established by X-ray diffraction. In complex 2, an anagostic C−H···Pt interaction is observed. All complexes are luminescent in the solid state at room temperature, showing important differences between the palladium and platinum complexes. Complex 2 shows two structured emission bands at high and low energies in the solid state, and the lifetimes are in agreement with excited states of triplet parentage. Density functional theory and time-dependent density functional theory calculations for complex 2 have been done. Values of IC50 were also calculated for the new complexes 1−4 against the tumor cell line HL-60. All of the new complexes were more active than cisplatin (up to 30-fold in some cases). The DNA adduct formation of the new complexes synthesized was followed by circular dichroism and electrophoretic mobility. Atomic force microscopy images of the modifications caused by the complexes on plasmid DNA pBR322 were also obtained.
- 1 July 2008
- Published by American Chemical Society (ACS) in Inorganic Chemistry
- Vol. 47 (15) , 6990-7001
New Palladium(II) and Platinum(II) Complexes with 9-Aminoacridine: Structures, Luminiscence, Theoretical Calculations, and Antitumor Activity
The new complexes [Pd(dmba)(N10-9AA)(PPh3)]ClO4 (1), [Pt(dmba)(N9-9AA)(PPh3)]ClO4 (2), [Pd(dmba)(N10-9AA)Cl] (3), and [Pd(C6F5)(N10-9AA)(PPh3)Cl] (4) (9-AA = 9-aminoacridine; dmba = N,C-chelating 2-(dimethylaminomethyl)phenyl) have been prepared. The crystal structures have been established by X-ray diffraction. In complex 2, an anagostic C−H···Pt interaction is observed. All complexes are luminescent in the solid state at room temperature, showing important differences between the palladium and platinum complexes. Complex 2 shows two structured emission bands at high and low energies in the solid state, and the lifetimes are in agreement with excited states of triplet parentage. Density functional theory and time-dependent density functional theory calculations for complex 2 have been done. Values of IC50 were also calculated for the new complexes 1−4 against the tumor cell line HL-60. All of the new complexes were more active than cisplatin (up to 30-fold in some cases). The DNA adduct formation of the new complexes synthesized was followed by circular dichroism and electrophoretic mobility. Atomic force microscopy images of the modifications caused by the complexes on plasmid DNA pBR322 were also obtained.
- 13 June 2007
- Published by American Chemical Society (ACS) in Inorganic Chemistry
- Vol. 46 (14) , 5448-5449
A Novel Metal-Binding Mode of Thymine Nucleobases: N(3) and O(4) Chelation
The syntheses and crystal structures of the first examples of an anionic 1-methylthymine [deprotonated at the endocyclic NH group N(3)] acting as a chelating ligand for the cis-Pd(C6F3H2)2 and cis-Pd(C6F5)2 moieties through N(3) and O(4) are reported.
- 13 June 2007
- Published by American Chemical Society (ACS) in Inorganic Chemistry
- Vol. 46 (14) , 5448-5449
A Novel Metal-Binding Mode of Thymine Nucleobases: N(3) and O(4) Chelation
The syntheses and crystal structures of the first examples of an anionic 1-methylthymine [deprotonated at the endocyclic NH group N(3)] acting as a chelating ligand for the cis-Pd(C6F3H2)2 and cis-Pd(C6F5)2 moieties through N(3) and O(4) are reported.
- 15 July 2006
- Published by American Chemical Society (ACS) in Inorganic Chemistry
- Vol. 45 (16) , 6347-6360
Palladium(II) and Platinum(II) Organometallic Complexes with the Model Nucleobase Anions of Thymine, Uracil, and Cytosine: Antitumor Activity and Interactions with DNA of the Platinum Compounds
Pd(II) and Pt(II) complexes with the anions of the model nucleobases 1-methylthymine (1-MethyH), 1-methyluracil (1-MeuraH), and 1-methylcytosine (1-MecytH) of the types [Pd(dmba)(μ-L)]2 [dmba = N,C-chelating 2-((dimethylamino)methyl)phenyl; L = 1-Methy, 1-Meura or 1-Mecyt] and [M(dmba)(L)(L‘)] [L = 1-Methy or 1-Meura; L‘ = PPh3 (M = Pd or Pt), DMSO (M = Pt)] have been obtained. Palladium complexes of the types [Pd(C6F5)(N−N)(L)] [L = 1-Methy or 1-Meura; N−N = N,N,N‘,N‘-tetramethylethylenediamine (tmeda), 2,2‘-bipyridine (bpy), or 4,4‘-dimethyl-2,2‘-bipyridine (Me2bpy)] and [NBu4][Pd(C6F5)(1-Methy)2(H2O)] have also been prepared. The crystal structures of [Pd(dmba)(μ-1-Methy)]2, [Pd(dmba)(μ-1-Mecyt)]2·2CHCl3, [Pd(dmba)(1-Methy)(PPh3)]·3CHCl3, [Pt(dmba)(1-Methy)(PPh3)], [Pd(tmeda)(C6F5)(1-Methy)], and [NBu4][Pd(C6F5)(1-Methy)2(H2O)]·H2O have been established by X-ray diffraction. The DNA adduct formation of the new platinum complexes synthesized was followed by circular dichroism and electrophoretic mobility. Atomic force microscopy images of the modifications caused by the platinum complexes on plasmid DNA pBR322 were also obtained. Values of IC50 were also calculated for the new platinum complexes against the tumor cell line HL-60. All the new platinum complexes were more active than cisplatin (up to 20-fold in some cases).
- 15 July 2006
- Published by American Chemical Society (ACS) in Inorganic Chemistry
- Vol. 45 (16) , 6347-6360
Palladium(II) and Platinum(II) Organometallic Complexes with the Model Nucleobase Anions of Thymine, Uracil, and Cytosine: Antitumor Activity and Interactions with DNA of the Platinum Compounds
Pd(II) and Pt(II) complexes with the anions of the model nucleobases 1-methylthymine (1-MethyH), 1-methyluracil (1-MeuraH), and 1-methylcytosine (1-MecytH) of the types [Pd(dmba)(μ-L)]2 [dmba = N,C-chelating 2-((dimethylamino)methyl)phenyl; L = 1-Methy, 1-Meura or 1-Mecyt] and [M(dmba)(L)(L‘)] [L = 1-Methy or 1-Meura; L‘ = PPh3 (M = Pd or Pt), DMSO (M = Pt)] have been obtained. Palladium complexes of the types [Pd(C6F5)(N−N)(L)] [L = 1-Methy or 1-Meura; N−N = N,N,N‘,N‘-tetramethylethylenediamine (tmeda), 2,2‘-bipyridine (bpy), or 4,4‘-dimethyl-2,2‘-bipyridine (Me2bpy)] and [NBu4][Pd(C6F5)(1-Methy)2(H2O)] have also been prepared. The crystal structures of [Pd(dmba)(μ-1-Methy)]2, [Pd(dmba)(μ-1-Mecyt)]2·2CHCl3, [Pd(dmba)(1-Methy)(PPh3)]·3CHCl3, [Pt(dmba)(1-Methy)(PPh3)], [Pd(tmeda)(C6F5)(1-Methy)], and [NBu4][Pd(C6F5)(1-Methy)2(H2O)]·H2O have been established by X-ray diffraction. The DNA adduct formation of the new platinum complexes synthesized was followed by circular dichroism and electrophoretic mobility. Atomic force microscopy images of the modifications caused by the platinum complexes on plasmid DNA pBR322 were also obtained. Values of IC50 were also calculated for the new platinum complexes against the tumor cell line HL-60. All the new platinum complexes were more active than cisplatin (up to 20-fold in some cases).